What is AGEN stock price today?

AGEN (Agenus Inc) stock is trading at $4.83 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is AGEN stock going up or down today?

AGEN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy AGEN stock now?

The decision to buy AGEN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is AGEN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for AGEN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is AGEN stock overvalued or undervalued?

Use our DCF valuation calculator to determine if AGEN is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is AGEN's P/E ratio?

P/E ratio data for AGEN will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is AGEN's market cap?

AGEN (Agenus Inc) has a market capitalization of $0.18 billion, making it a small-cap stock.

What is AGEN's price to book ratio?

AGEN trades at a price-to-book (P/B) ratio of 218.61, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does AGEN pay dividends?

AGEN does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is AGEN's dividend yield?

AGEN does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is AGEN stock a good long-term investment?

AGEN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is AGEN's revenue growth rate?

AGEN has shown revenue growth of 0.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, AGEN is profitable with a profit margin of 0.0%. This indicates the company generates 0.0 cents of profit for every dollar of revenue.

What are the risks of investing in AGEN?

Key risks for AGEN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does AGEN compare to its competitors?

Compare AGEN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize AGEN's performance and positioning.

What is AGEN's stock price target for 2026?

Our AI model provides price targets for AGEN based on fundamental analysis: Bull case $6.28 (+30%), Base case $5.55 (+15%), Bear case $4.35 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about AGEN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for AGEN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is AGEN's next earnings report?

AGEN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

AGEN - Agenus Inc

NYSE * Health Care * Biotechnology

$4.83

+$0.11 (+2.33%)

About Agenus Inc

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Key Statistics

Market Cap

$181.24M

P/B Ratio

218.61

Revenue Growth

+0.3%

Profit Margin

0.0%

Employees

How AGEN Compares to Peers

AGEN has the fastest revenue growth among competitors

AGEN is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
AGEN(This stock)	$181.24M	N/A	0%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.50B	20.5	-0%	0.1%	vs BIIB

Agenus Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.agenusbio.com
Sector: Health Care
Industry: Biotechnology

AGEN - Agenus Inc

About Agenus Inc

AGEN Key Statistics

How AGEN Compares to Peers

Agenus Inc Company Information

AGEN Lician Score

AGEN Financial Snowflake

Upcoming Events for AGEN